Clinical Trials Logo

Hyperphosphatemia clinical trials

View clinical trials related to Hyperphosphatemia.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06406140 Enrolling by invitation - Clinical trials for End-stage Renal Disease

Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients

Start date: March 15, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to learn if Niacin has an effect on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in End-stage renal disease (ESRD) patients undergoing hemodialysis. It will also learn about the safety of Niacin. The main questions it aims to answer are: - Does Niacin lower lipoprotein (a) concentration? - Does Niacin treat hyperphosphatemia in End-stage renal disease (ESRD) patients undergoing hemodialysis? Researchers will compare Niacin to a control group (taking no drug) to see if drug Niacin works to treat hyperphosphatemia and lower lipoprotein (a) concentration. Participants will: - Take drug Niacin or no drug every day for 3 months - Visit the clinic once every 2 weeks for checkups and tests All Patients will be subjected to the following: 1. Informed consent. 2. Demographics and history taking: Using Patient Data sheet. 3. Laboratory evaluation including: Kidney function tests: blood urea,serum creatinine, albumin ,uric acid. Complete blood count (CBC). Lipid profile:Lipoprotein (a),total cholesterol,triglyceride,high density lipoprotein (HDL), low density lipoprotein (LDL). Phosphorous, calcium, sodium, parathyroid hormone (PTH), alkaline phosphatase (ALP). C-reactive protein (CRP).

NCT ID: NCT02237534 Enrolling by invitation - Clinical trials for Renal Insufficiency, Chronic

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

LAVALIER
Start date: September 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.